The effects of high dose inhaled beclomethasone dipropionate on glucose and lipid profiles in normal and diet controlled diabetic subjects

Ebden, P; McNally, PG; Samanta, A.; Fancourt, G.J.

doi:10.1016/s0954-6111(89)80198-2

Cited by 18 publications

(9 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, 14 normal subjects and 10 non-asthmatic patients with diet-controlled type 2 diabetes mellitus took inhaled placebo for 2 weeks followed by inhaled beclomethasone dipropionate (2 mg/day) for 2 weeks. 22 Inhaled glucocorticoid therapy did not significantly alter glucose tolerance tests and insulin levels after 2 weeks. However, %HbA1c and SMBG were not measured, and the authors comment that an effect might have been observed with prolonged therapy, which also was not explored in the present study.…”

Section: Discussionmentioning

confidence: 88%

The Effect of an Inhaled Corticosteroid on Glucose Control in Type 2 Diabetes

Faul¹,

Wilson²,

Chu³

et al. 2009

Clinical Medicine & Research

View full text Add to dashboard Cite

Objective:To determine the effect of inhaled corticosteroid (ICS) therapy on glucose control in adults with type 2 diabetes mellitus and coexisting asthma or chronic obstructive pulmonary disease (COPD).Design: A prospective randomized, double-blind, double-dummy placebo-controlled, crossover investigation of inhaled steroids and oral leukotriene blockers. Setting:A United States Department of Veterans Affairs Health Care System outpatient setting.Participants: Adults with type 2 diabetes and asthma or COPD.Methods: Subjects (n=12) were randomized to receive either inhaled fluticasone propionate (440 µg twice daily) and oral placebo, or inhaled placebo and oral montelukast (10 mg/day). After 6 weeks, subjects were switched to the opposite therapy for 6 weeks. The primary outcome measure was the change in the percentage of glycosylated hemoglobin (%HbA1c) at 6 weeks relative to the baseline value.Results: Ten patients completed the study. The difference between the mean within-subject changes in %HbA1c associated with 6-week periods of fluticasone and the mean changes associated with montelukast therapy was small but statistically significant (mean difference=0.25; P<0.025). Neither fluticasone nor oral montelukast therapy for 6 weeks led to a significantly different mean % HbA1c compared with the relevant baseline (mean differences=0.11 and -0.14, respectively). Conclusion:The absence of a clinically significant within-subject difference in the changes in %HbA1c associated with fluticasone versus oral montelukast therapy, or between either therapy or baseline does not warrant recommending changes in therapy for asthma or diabetes in patients with these co-morbid conditions. However, we suggest that clinicians carefully monitor blood glucose control when diabetic patients initiate ICS, especially with higher dosages.

show abstract

Section: Discussionmentioning

confidence: 88%

The Effect of an Inhaled Corticosteroid on Glucose Control in Type 2 Diabetes

Faul¹,

Wilson²,

Chu³

et al. 2009

Clinical Medicine & Research

View full text Add to dashboard Cite

show abstract

“…67 However, both healthy nondiabetics and diet-controlled adult diabetics showed normal glucose tolerance and lipid profiles while taking inhaled beclomethasone dipropionate in doses ranging from 1,000 to 2,000 J.Lg/d. 68 Kiviranta and Turpeinen 69 reported an improvement in glucose intolerance in 15 poorly controlled asthmatics after the initiation of inhaled corticosteroid therapy. This effect was athibuted to a reduction in stress reactions induced by poorly controlled asthma.…”

Section: Glucose Intolerancementioning

confidence: 99%

Adverse Effects of Corticosteroid Therapy for COPD

McEvoy

Niewoehner

1997

Chest

139

View full text Add to dashboard Cite

“…Nevertheless, a more recent small randomized trial examining whether inhaled fluticasone propionate (440 μg twice daily for 6 weeks) led to changes in HbA1c levels in patients with type-2 diabetes and asthma or COPD also observed no effect of ICS treatment [37]. Finally, another small study investigating the effects of inhaled beclometasone dipropionate (2,000 μg/day for 2 weeks) on normal and elderly subjects found no effects on glucose metabolism [38]. …”

Section: Evidence Linking Ics To Diabetes Risk In Copd Patientsmentioning

confidence: 99%

Current Perspectives on the Contribution of Inhaled Corticosteroids to an Increased Risk for Diabetes Onset and Progression in Patients with Chronic Obstructive Pulmonary Disease

2014

View full text Add to dashboard Cite

Recent studies have suggested that inhaled corticosteroids (ICS) play a role in the development of hyperglycemia and type-2 diabetes in patients with chronic obstructive pulmonary disease (COPD). Nevertheless, this corticosteroid-associated adverse effect remains controversial. Moreover, the pharmacokinetic properties and patient characteristics that might contribute to an increased risk for diabetes upon ICS exposure have not been thoroughly investigated. In the present review, we critically discuss current evidence regarding the relationship between ICS therapy in COPD patients and an increased risk for the incidence and progression of type-2 diabetes. In addition, we address therapeutic conditions, clinical implications, and future perspectives related to this potentially important ICS-associated adverse effect in COPD patients.

show abstract

The effects of high dose inhaled beclomethasone dipropionate on glucose and lipid profiles in normal and diet controlled diabetic subjects

Cited by 18 publications

References 3 publications

The Effect of an Inhaled Corticosteroid on Glucose Control in Type 2 Diabetes

The Effect of an Inhaled Corticosteroid on Glucose Control in Type 2 Diabetes

Adverse Effects of Corticosteroid Therapy for COPD

Current Perspectives on the Contribution of Inhaled Corticosteroids to an Increased Risk for Diabetes Onset and Progression in Patients with Chronic Obstructive Pulmonary Disease

Contact Info

Product

Resources

About